参芪扶正注射液联合化疗治疗晚期肺癌临床观察  

Effects of Shengqi Fuzheng Injection Combined Chemotherapy on Patients with Advanced Lung Cancer

作　　者：李铁文[1] 向丽[1] 童方友 张春虎[2] 

机构地区：[1]湖南省桃源县人民医院,湖南桃源415700 [2]中南大学湘雅医院中西医结合研究所,湖南长沙410008

出　　处：《现代生物医学进展》2009年第10期1917-1919,共3页Progress in Modern Biomedicine

基　　金：湖南省自然科学基金(05JJ30175)

摘　　要：目的:探讨参芪扶正注射液联合化疗治疗晚期肺癌、改善化疗不良反应的作用。方法:本研究采用前瞻性开放性病例对照研究,将69例肺癌患者随机分为治疗组(36例)和对照组(33例)。对照组采用NP化疗方案;治疗组在NP化疗方案基础上加用参芪扶正注射液250mL静脉滴注,每天1次,28天为1个周期。所有患者均用药2个周期。观察近期疗效、生活质量变化、不良反应及免疫功能变化。结果:治疗2个周期后,治疗组患者在疗效控制情况、生活质量Karnofsky评分、不良反应与对照组比均明显改善(P<0.01)。结论:参芪扶正注射液联合化疗治疗晚期肺癌,可显著提高疗效,提高生活质量,减轻化疗的毒副反应。Objective： To investigate the clinical efficacy of Shenqi Fuzheng Injection （SF I） combined with chemotherapy in treating patients with advanced lung cancer. Methods： The forward-looking open case method was used and 69 patients with advanced lung cancer were enrolled and randomly divided into two groups： treatment group of 36 cases with Shenqi SFI combined NP regimen and control group of 33 cases with NP regimen alone. All patients were treated with regimen for 28 days as one therapeutic cycle. The therapeutic efficiency was evaluated after two cycles of treatment by observing the changes of short-term efficacy, quality of life change, and adverse reaction. Results： Compared with the control group, the treatment group patients are in the curative effect control situation, while the quality of life Karnofsky score and adverse reaction are significantly improved （P〈0.01） after treated for 2 cycles. Conclusions： SFI combined NP regimen can obviously enhance the curative effect, improve the quality of life and reduce the chemotherapy adverse reaction in the patients with advanced lung cancer.

关 键 词：参芪扶正注射液 化疗 肺癌 

分 类 号：R285[医药卫生—中药学] R743.31[医药卫生—中医学]